3 Shares Analysts Hate: GlaxoSmithKline plc, Standard Chartered PLC And Anglo American plc

Here’s why GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN) and Anglo American plc (LON:AAL) are out of favour with City experts.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Right now, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), Standard Chartered (LSE: STAN) and Anglo American (LSE: AAL) are not winning friends among City analysts. Here’s why.


It wasn’t so long ago that GlaxoSmithKline was the City experts’ favoured pharmaceuticals firm, while AstraZeneca was thoroughly unloved. How times change! Over the past year we’ve seen a series of downgrades to Glaxo’s earnings forecasts (from 114p a share 12 months ago to 80p a share today), along with a swing to negative recommendations; more analysts now rate Glaxo a Sell than a Buy.

Underwhelming Q1 results last month, and the board’s decision to hold the dividend at 80p a share for the next three years, saw bearish analysts reiterate their negative stance, and a number of previously bullish brokers move from Buy to Neutral.

Even Glaxo’s house broker Citigroup sounded downbeat, mentioning — among other things — Glaxo’s “inability to compete on a level playing field in China” (since last year’s bribery scandal) and “constrain[ed] relative commercial effectiveness in the US compared with peers” (due to an onerous US corporate integrity agreement that still has 2.5 years to run).

Nevertheless, private investors taking a longer-term view than CIty number crunchers may feel Glaxo’s shares are attractive at current depressed sub-£14 levels with a juicy 5.8% dividend yield — albeit with the yield being static for three years.

Standard Chartered

Analysts’ earnings downgrades for Standard Chartered over the past year have been even more dramatic than those for Glaxo, moving from 136p a share 12 months ago to 87p today. Nearly twice as many analysts now rate the troubled Asia-focused bank — which has had a boardroom clear out — as a Sell than as a Buy.

Analysts at Jefferies International are uber-bears on StanChart, and have recently further slashed their target price from 722p to 656p (the shares are currently trading at over £10). Many analysts who are negative on the stock are concerned about the bank’s capital ratios — and the impact of potential asset sales/dividend cut/rights issue — but Jefferies’ analysts are particularly downbeat. They believe that whatever route StanChart takes to improve its capital ratios “the earnings power of the bank is likely to be far below what the consensus expects”.

The consensus currently has StanChart on a P/E of 12, with a dividend yield of 4.6%. On the face of it, the valuation is attractive, but, while I don’t view the bank as bleakly as Jefferies, I think it could be prudent to wait and see exactly what the new chief executive’s plans are.

Anglo American

Mining has been far from the City experts’ best-loved sector for some time. But Anglo American — which currently has twice as many Sell ratings as Buy recommendations — is markedly less popular than its big FTSE 100 peers BHP Billiton, Rio Tinto and Glencore. And earnings downgrades for Anglo American over the past year (from 129p a share 12 months ago to 68p a share today), make the downgrades to Glaxo and StanChart appear downright mild!

Of course, the whole mining industry has been hit by falling commodity prices. Anglo American, though, has seen additional issues; including, a hangover from ill-timed acquisitions, slow progress on asset disposals and labour unrest.

Bearish equity analysts are concerned about the pace of restructuring and cost cutting, and cash flow and dividend sustainability (the yield is currently 5.6%). Global credit ratings agency Fitch has also chipped in, commenting: “Elevated leverage, which was driven by the intensive capital spending of previous years remains a primary risk, in our view, and is reflected in the negative outlook”.

Anglo American’s P/E of 14.5 is lower than its Footsie rivals, but I believe Rio Tinto has a better risk-reward profile.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Modern suburban family houses with car on driveway
Investing Articles

Should I snap up Taylor Wimpey shares at £1.30?

With the Taylor Wimpey share price down by almost 30% this year, should I snap up some shares while it's…

Read more »

Young female analyst working at her desk in the office
Investing Articles

How I’m finding shares to buy now – and keep for a decade

Our writer has been looking for shares to buy using an approach that looks both at long-term profit prospects and…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

What’s happening to the Petrofac (PFC) share price?

The Petrofac (LON:PFC) share price has had a seriously erratic year so far. I take a look at the latest…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

The Aviva share price is flying! Should I buy this 7% yield?

Despite recent gains, Roland Head thinks the Aviva share price could still be too cheap.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

Here’s 1 passive income opportunity not to be missed!

This Fool details a passive income opportunity that could bolster his holdings, and the shares trading at cheap levels too.

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Legal & General share price is dirt-cheap with a juicy dividend yield!

Jabran Khan takes a closer look at the Legal & General share price which looks like an opportunity to boost…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

If I’d invested £1,000 in this top lithium stock 5 years ago, here’s how much I’d have now!

This lithium stock has gone from strength to strength over the past year. But has it flown too high, or…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A growth stock with a price-to-earnings ratio of just 9.7! Should I buy Yalla?

I'm generally not too keen on investing in dollar-demonated stocks at the moment. But Yalla, with its low price-to-earnings ratio,…

Read more »